S Pinder

2.2k total citations
62 papers, 1.6k citations indexed

About

S Pinder is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, S Pinder has authored 62 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cancer Research, 24 papers in Oncology and 23 papers in Pathology and Forensic Medicine. Recurrent topics in S Pinder's work include Breast Cancer Treatment Studies (28 papers), Breast Lesions and Carcinomas (23 papers) and Global Cancer Incidence and Screening (12 papers). S Pinder is often cited by papers focused on Breast Cancer Treatment Studies (28 papers), Breast Lesions and Carcinomas (23 papers) and Global Cancer Incidence and Screening (12 papers). S Pinder collaborates with scholars based in United Kingdom, Canada and United States. S Pinder's co-authors include Ian O. Ellis, C.W. Elston, J.F.R. Robertson, Emad A. Rakha, D.M. Sibbering, A.R.M. Wilson, C.W. Elston, R.W. Blamey, R.W. Blamey and Sarah Lewis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

S Pinder

60 papers receiving 1.5k citations

Peers

Countries citing papers authored by S Pinder

Since Specialization

Citations

This map shows the geographic impact of S Pinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Pinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Pinder more than expected).

Fields of papers citing papers by S Pinder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Pinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Pinder. The network helps show where S Pinder may publish in the future.

Co-authorship network of co-authors of S Pinder

This figure shows the co-authorship network connecting the top 25 collaborators of S Pinder. A scholar is included among the top collaborators of S Pinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Pinder. S Pinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study 2025 ·ESMO Open ·Robert C. Stein, A. Marshall, (unknown), Luke Hughes‐Davies, I. Macpherson, (unknown), (unknown), Peter Canney, Helena Earl, (unknown), Jane Bayani, Peter Hall, Christopher J. McCabe, (unknown), (unknown), S Pinder, Leila Rooshenas, (unknown), J. M. S. Bartlett, (unknown)	1
2	Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer 2014 ·Breast Cancer Research and Treatment ·Sheeba Irshad, Cheryl Gillett, S Pinder, Roger A’Hern, Mitch Dowsett, Ian O. Ellis, John M.S. Bartlett, Judith M. Bliss, A M Hanby, Stephen Johnston, Peter Barrett‐Lee, Peter Ellis, Andrew Tutt	4
3	MYC amplification in breast cancer: A chromogenic in situ hybridisation study 2007 ·Laboratory Investigation ·(unknown), Robin L. Jones, Maryou B. Lambros, Edurne Arriola, Kay Savage, Michelle A. James, S Pinder, (unknown)	1
4	Total Loss of MHC Class I is an Independent Indicator of Good Prognosis in Breast Cancer 2005 ·SHILAP Revista de lepidopterología ·Zahra Madjd, Ian Spendlove, Ian O. Ellis, S Pinder, LG Durrant	5
5	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1 2004 ·British Journal of Cancer ·Emad A. Rakha, S Pinder, Claire E. Paish, Ian O. Ellis	29
6	Best Practice No 179 2004 ·Journal of Clinical Pathology ·Ian O. Ellis, S Humphreys, Michael Michell, S Pinder, Clive Wells, H.D. Zakhour	86
7	Prognostic factors for patients with hepatic metastases from breast cancer 2003 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·Lynda Wyld, Eleanor Gutteridge, S Pinder, J.N. Vauthey	4
8	Loss of CD59 expression in breast tumours correlates with poor survival 2003 ·The Journal of Pathology ·Zahra Madjd, S Pinder, Claire E. Paish, Ian O. Ellis, J Carmichael, LG Durrant	72
9	Prognostic significance of BRCA1 expression in sporadic breast carcinomas 2003 ·The Journal of Pathology ·Hannah Lambie, (unknown), S Pinder, JA Bell, P.M. Wencyk, (unknown), R. Douglas Macmillan, Ian O. Ellis	48
10	An audit of ‘equivocal’ (C3) and ‘suspicious’ (C4) categories in fine needle aspiration cytology of the breast 2001 ·Cytopathology ·Rahul Deb, P.N. Matthews, C.W. Elston, Ian O. Ellis, S Pinder	33
11	C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. 1999 ·PubMed ·Peter C. Willsher, S Pinder, Julia M.W. Gee, Ian O. Ellis, Stephen Chan, Robert I. Nicholson, R.W. Blamey, J.F.R. Robertson	25
12	Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates 1997 ·Cytopathology ·David Snead, (unknown), S Pinder, A. Evans, A.R.M. Wilson, R.W. Blamey, C.W. Elston, Ian O. Ellis	28
13	C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators 1996 ·British Journal of Cancer ·(unknown), S Pinder, (unknown), JA Bell, P.M. Wencyk, WJ Gullick, (unknown), (unknown), RW Blamey, CW Elston, Ian O. Ellis	106
14	The role of pre‐operative diagnosis in breast cancer 1996 ·Histopathology ·S Pinder, C.W. Elston, Ian O. Ellis	28
15	Screening interval breast cancers: mammographic features and prognosis factors. 1996 ·Radiology ·H.C. Burrell, D.M. Sibbering, A.R.M. Wilson, S Pinder, Andrew Evans, L.J. Yeoman, C.W. Elston, Ian O. Ellis, R.W. Blamey, J.F.R. Robertson	159
16	Is ipsilateral mammography worthwhile in paget's disease of the breast? 1996 ·Clinical Radiology ·(unknown), Andy Evans, S Pinder, A.R.M. Wilson, Ian O. Ellis, L.J. Yeoman	45
17	Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma 1995 ·Histopathology ·(unknown), S Pinder, D.M. Sibbering, M Galea, C.W. Elston, R.W. Blamey, J.F.R. Robertson, Ian O. Ellis	138
18	98. Mammographic features of interval cancers and prognosis compared with screen detected and symptomatic breast cancers 1995 ·The Breast ·H.C. Burrell, D.M. Sibbering, S Pinder, A.R.M. Wilson, (unknown), L.J. Yeoman, C.W. Elston, (unknown), R.W. Blamey, J.F.R. Robertson	2
19	Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. 1994 ·Radiology ·Andrew Evans, S Pinder, Ian O. Ellis, Mark Sibbering, C.W. Elston, David Poller, R. Wilson	42
20	The expression of alpha B‐crystallin in epithelial tumours: A useful tumour marker? 1994 ·The Journal of Pathology ·S Pinder, M Balsitis, Ian O. Ellis, Michael Landon, R. John Mayer, James Lowe	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact